| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | lanifibranor stéatohépatite associée à un dysfonctionnement métabolique (MASH) BreakthroughFast Track | Phase 3 | — | Subscribe to access the data. | Small Molecules | Digestive System | |
Phase 3 topline data readout example | lanifibranor stéatohépatite associée à un dysfonctionnement métabolique (MASH) BreakthroughFast Track | Phase 3 | — | Subscribe to access the data. | Small Molecules | Digestive System | |
Phase 3 topline data readout example | lanifibranor stéatohépatite associée à un dysfonctionnement métabolique (MASH) BreakthroughFast Track | Phase 3 | — | Subscribe to access the data. | Small Molecules | Digestive System |
Recent Updates
Recently added Catalysts
Inventiva S.A. - American Depository Shares$4.3
-0.17 (-3.75%)
C 47Pipeline Score Fair Value Biotech · Commercial
Market Cap
1.06 B
EPS
-2.84
P/E Ratio
-
Value Trade
4.99 M
-10.42 %
Week
-4.88 %
1 Month
-22.12 %
3 Month
26.43 %
6 Month
-65.86 %
5 Year
-66.49 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
582.53 K
52 Week Range
2.85 - 7.98
% held by Insiders
6.26 %
% held by Institutions
16.63 %
Enterprise Value
1.01 B
Total Shares
208.92 M
Short %
0.49 %
Float Shares
195.77 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Inventiva S.A. - American Depository Shares
87Total events
3Upcoming
17Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 3
Event history 84
Q3 2026
▼Runway Guidance UpdateCorporate
Cash runway guidance: financing until end of Q3 2026 prior to offering
Jun 30, 2026
◆Equity OfferingCorporate
General meeting of shareholders to approve issuance of New EIB Warrants
Jun 25, 2026
●Oral PresentationPresentation
Portzamparc BNP Paribas group mid & small caps conference 2026, Paris
Jun 12, 2026
▲Debt Royalty FinancingCorporate
Repaid EIB Loans in full (€62M) and repurchased portion of EIB Warrants (€50M)
Jun 3, 2026
◆Oral PresentationPresentation
Inventiva presentation at 2026 Jefferies Global Healthcare Conference
MASHsource ↗
Jun 2, 2026
Jun 2, 2026
▲Debt Royalty FinancingCorporate
New debt financing with BlackRock and Claret Capital Partners up to €130 million
Jun 2026
▲Equity OfferingCorporate
Repurchase and cancellation of EIB Tranche A Warrants and 700,000 EIB Tranche B Warrants
Drug Pipeline Intelligence
C47
Pipeline Score $1.2B
Pipeline ValueFair Value
Valuation Signal3
Drugs Scored1.2x
rNPV / MCap Top 69%
Micro Cap (rank 283 of 911)
Percentile RankInventiva S.A. - American Depository Shares carries a moderate pipeline score (47/100), with $4.0B risk-adjusted pipeline value, led by Lanifibranor in Nonalcoholic Fatty Liver Disease (NAFLD) (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lanifibranor Small molecule | Nonalcoholic Fatty Liver Disease (NAFLD) | Phase 2 | NCT03459079 | 86% | $3.4B | COMPLETED | 128 | - | - | Jun 1, 2023 | - | Sep 19, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
lanifibranor BreakthroughFast Track | T2D and NAFLD | Phase 2 | 2023-09-28 | In a Phase II trial, lanifibranor demonstrated a 44% reduction in hepatic fat after 24 weeks of treatment in patients with T2D and NAFLD, with a significantly higher proportion achieving over 30% liver triglyceride reduction compared to placebo. Read More | INVENTIVA S.A. A joint-stock company ( société anonyme ) with a share capital of 517,528.07 euros Registered office: 50, rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255 INTERIM F Read More | |
lanifibranor BreakthroughFast Track | T2D and NAFLD | Phase 2 | 2023-09-28 | In a Phase II trial, lanifibranor demonstrated a 44% reduction in hepatic fat after 24 weeks of treatment in patients with T2D and NAFLD, with a significantly higher proportion achieving over 30% liver triglyceride reduction compared to placebo. Read More | INVENTIVA S.A. A joint-stock company ( société anonyme ) with a share capital of 517,528.07 euros Registered office: 50, rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255 INTERIM F Read More | |
lanifibranor BreakthroughFast Track | T2D and NAFLD | Phase 2 | 2023-09-28 | In a Phase II trial, lanifibranor demonstrated a 44% reduction in hepatic fat after 24 weeks of treatment in patients with T2D and NAFLD, with a significantly higher proportion achieving over 30% liver triglyceride reduction compared to placebo. Read More | INVENTIVA S.A. A joint-stock company ( société anonyme ) with a share capital of 517,528.07 euros Registered office: 50, rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255 INTERIM F Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IVA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IVA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IVA▼ -5.1%on this news
Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants
Inventiva has successfully completed the restructuring of EIB warrants, issuing approximately 15.7 million new warrants to the European Investment Bank. This move is part of a broader refinancing strategy aimed at optimizing the company's capital structure. The new warrants replace older ones, eliminating specific anti-dilution protections and enhancing financial flexibility for the development of lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis.
Read more →IVAInventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
Inventiva has successfully repaid its existing EIB loans amounting to approximately €62 million and repurchased a portion of EIB warrants for €50 million. Additionally, the company issued the first two tranches of a new debt financing transaction, raising €75 million. These actions are part of a broader strategy to enhance its financial stability and support its clinical development efforts.
Read more →IVATranslation for information purpose only INVENTIVA French soci t Anonyme with a Board of Directors with a share capital of EUR 2,090,074.75 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies
INVENTIVA is scheduled to hold its ordinary and extraordinary general meeting on June 30, 2026, in Paris. The meeting will address various resolutions, including the approval of the financial statements that disclose a net accounting loss of EUR 207,965,630.56 for the year ending December 31, 2025. Additionally, resolutions will focus on the approval of a subscription agreement with Samsara BioCapital L.P. and discussions on executive compensation. These developments reflect the company's ongoing financial challenges.
Read more →IVACopyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved styleIPC Instructions to The Bank of New York, as Depositary (Must be received prior to 12:00 PM Eastern Time
Inventiva S.A. is set to hold a Joint Ordinary & Extraordinary General Meeting of Shareholders, where shareholders will vote on several proposals. Significant decisions include the issuance of share subscription warrants and the delegation of authority to the Board of Directors regarding share capital increases. The meeting will also address corporate governance, such as the approval of compensation policies for directors. This marks a critical step in aligning the company’s articles of association with current laws and regulations.
Read more →IVA▼ -14.3%on this newsshared move
Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris
Inventiva has announced the resumption of trading for its ordinary shares on Euronext Paris, effective from 3:30 p.m. CEST on June 2, 2026. The trading halt was initiated at the company's request due to a Debt Financing Transaction and the offering of American Depositary Shares. Inventiva is focused on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH) and is currently evaluating lanifibranor in a Phase 3 clinical trial.
Read more →IVA▼ -14.3%on this newsshared move
Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout
Inventiva has announced a comprehensive capital structure optimization involving €130 million in new debt financing and a $120 million equity offering. This strategy aims to simplify its capital structure by repurchasing existing warrants and extending its cash runway into early 2028. The company reiterated its confidence in achieving a Phase 3 readout for lanifibranor in Q4 2026, followed by a potential regulatory filing in H1 2027.
Read more →IVA▼ -14.3%on this newsshared move
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
Inventiva has announced a temporary halt in trading of its ordinary shares on Euronext Paris, effective from 9:00 a.m. CEST. This decision was made at the company's request in anticipation of a forthcoming financing transaction. Trading is expected to resume later today at approximately 3:30 p.m. CEST, coinciding with the expected start of trading on the Nasdaq Global Market.
Read more →IVAInventiva Reports 2026 First Quarter Financial Information¹
Inventiva reported its financial results for Q1 2026, showing cash and cash equivalents of €75 million. The company did not generate any revenue during this period, similar to Q1 2025. Looking ahead, Inventiva anticipates key milestones, including topline results from its NATiV3 trial in late 2026. However, uncertainties regarding future funding and ongoing losses remain.
Read more →IVAInventiva to Present at 2026 Jefferies Global Healthcare Conference
Inventiva, a clinical-stage biopharmaceutical company, announced that its CEO, Andrew Obenshain, will present at the 2026 Jefferies Global Healthcare Conference in New York City. The presentation is scheduled for June 3, 2026, and will focus on the company's development of therapies for metabolic dysfunction-associated steatohepatitis (MASH). Additionally, Inventiva leadership will hold one-on-one meetings during the conference.
Read more →IVATranslation for information purpose only INVENTIVA Soci t Anonyme with a Board of Directors With a share capital of EUR 2,090,074.75 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Registe
INVENTIVA will hold an Ordinary and Extraordinary General Meeting on June 30, 2026, to discuss the financial statements for the fiscal year ending December 31, 2025. The meeting will address the substantial net accounting loss of EUR 207,965,630.56. Additionally, the company has not distributed any dividends since its incorporation, reflecting its ongoing financial challenges. The proceedings will include an analysis of various management and statutory auditor reports.
Read more →IVAInventiva présentera lors de la 2026 Jefferies Global Healthcare Conference
Inventiva will present at the 2026 Jefferies Global Healthcare Conference in New York City. CEO Andrew Obenshain is scheduled to speak on June 3, 2026. The company is focused on developing oral therapies for metabolic dysfunction-related steatohepatitis (MASH) and is currently evaluating lanifibranor in a pivotal Phase 3 clinical trial.
Read more →IVAInventiva to Present Abstracts at the EASL Congress 2026
Inventiva will present two abstracts at the EASL Congress 2026 in Barcelona, highlighting their drug candidate lanifibranor. This oral therapy targets metabolic dysfunction-associated steatohepatitis (MASH) and has received both Breakthrough Therapy and Fast Track designations from the FDA. The company aims to showcase its advancements in treating this chronic liver disease.
Read more →IVAInventiva présentera plusieurs abstracts lors de l’EASL Congress 2026
Inventiva announced the presentation of two abstracts at the EASL Congress 2026, scheduled for May 27-30 in Barcelona. The company will showcase its lead candidate, lanifibranor, an oral pan-PPAR agonist targeting metabolic dysfunction-related steatohepatitis (MASH). Lanifibranor has received Breakthrough Therapy and Fast Track designations from the FDA.
Read more →IVAInventiva renforce son équipe de direction à l’approche des résultats de Phase 3 du lanifibranor
Inventiva has announced the appointment of three new executives to strengthen its leadership team as it prepares for the Phase 3 results of lanifibranor. Axel-Sven Malkomes joins as CFO, Susan Coles as Legal Director, and Pamela Herbster as HR Director, bringing extensive experience in their respective fields. These appointments are crucial as the company anticipates significant developments in the fourth quarter of 2026.
Read more →IVAInventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F
Inventiva has filed its 2025 Universal Registration Document and Annual Report on Form 20-F, providing insights into its financial performance and management report for the year ending December 31, 2025. The documents are accessible via the company's website and regulatory bodies. Inventiva continues to develop therapies for metabolic dysfunction-associated steatohepatitis (MASH), particularly through its pivotal Phase 3 trial of lanifibranor.
Read more →IVAInventiva reports 2025 full year results and provides a business update
Inventiva reported its financial results for 2025, highlighting revenues of €4.5 million and a net loss of €354.1 million. The company completed a public offering, raising approximately $172.5 million, and has a cash runway expected until mid-Q1 2027. Key milestones include the anticipated topline results of the NATiV3 Phase 3 trial in Q4 2026 and potential milestone payments from the sale of odiparcil.
Read more →IVAInventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results
Inventiva has announced the release date for its 2025 full-year financial results, scheduled for March 30, 2026. Following this, a conference call will be held on March 31, 2026, to discuss the results and answer questions from participants. The company continues to focus on developing therapies for metabolic dysfunction-associated steatohepatitis.
Read more →IVAInventiva to Participate in Four Upcoming March 2026 Investor Conferences
Inventiva, a clinical-stage biopharmaceutical company, will participate in four investor conferences in March 2026. These events include presentations and one-on-one meetings, allowing the company to showcase its developments in treating metabolic dysfunction-associated steatohepatitis (MASH). The leadership will engage with investors at prominent conferences in Boston and Miami.
Read more →IVAInventiva reports preliminary 2025¹ fiscal year financial results
Inventiva reported its preliminary financial results for the fiscal year 2025, revealing cash and cash equivalents of €99.3 million. The company experienced an increase in net cash used in operating activities and a significant drop in revenues. Despite these challenges, Inventiva's financing activities provided a positive cash flow, allowing operations to continue until early 2027.
Read more →IVAInventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Inventiva has announced that its CEO, Andrew Obenshain, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026. The event is scheduled for February 11-12, 2026, in New York City. The company will also engage in one-on-one meetings during the conference, highlighting its focus on developing therapies for metabolic dysfunction-associated steatohepatitis.
Read more →IVAInventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference
Inventiva has announced that its CEO, Andrew Obenshain, will present at the 44th Annual J.P. Morgan Healthcare Conference. The event is scheduled for January 12-15, 2026, in San Francisco, California. The company will also hold one-on-one investor meetings on January 14, 2026, to discuss its clinical-stage developments, particularly in treating metabolic dysfunction-associated steatohepatitis.
Read more →IVAInventiva présentera à la 44e conférence annuelle J.P. Morgan Healthcare
Inventiva has announced that its CEO, Andrew Obenshain, will present at the 44th annual J.P. Morgan Healthcare Conference. The event will take place from January 12 to 15, 2026, in San Francisco. During the conference, Inventiva's management will also hold one-on-one meetings with investors. The presentation will focus on the company's developments in therapies for metabolic dysfunction-related steatohepatitis.
Read more →IVA▼ -7.6%on this news
Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025
Inventiva announced the results of its Combined Shareholders' Meeting held on November 27, 2025. All proposed resolutions were adopted except for one, which was negatively recommended by the Board. The meeting also approved the CEO's compensation policy. Inventiva continues to focus on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH).
Read more →IVA▼ -7.6%on this news
Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunie le 27 novembre 2025
Inventiva held its Mixed General Assembly on November 27, 2025, where shareholders approved all resolutions except one, which was negatively recommended by the Board. The assembly also confirmed the remuneration policy for the CEO. Inventiva is focused on developing oral therapies for metabolic dysfunction-related steatohepatitis and is currently evaluating Lanifibranor in a Phase 3 clinical trial.
Read more →IVA▼ -5.7%on this news
Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
Inventiva has announced a temporary halt in trading of its ordinary shares on Euronext Paris at its request. This pause is related to the confirmation of allocations and pricing for its public offering of American Depositary Shares (ADSs). Trading is anticipated to resume later the same day, coinciding with the expected start of ADS trading on Nasdaq.
Read more →IVA▼ -5.7%on this news
Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
Inventiva announced a temporary suspension of its ordinary shares on Euronext Paris, effective from 9:00 AM CET. This decision is part of a public offering in the U.S. for new American Depositary Shares (ADSs). Trading is expected to resume later the same day at approximately 3:30 PM CET.
Read more →IVA▼ -5.7%on this newsshared move
Inventiva announces launch of public offering
Inventiva has announced a public offering of approximately $125 million in American Depositary Shares (ADSs) to fund its ongoing Phase 3 clinical trial for MASH. The offering will be conducted in the United States and is subject to market conditions. The proceeds will also support commercialization efforts and general corporate purposes.
Read more →IVA▼ -5.7%on this newsshared move
Inventiva annonce le lancement d'une offre au public
Inventiva has announced a public offering of approximately $125 million in American Depositary Shares (ADSs) to fund its ongoing Phase 3 NATiV3 clinical trial and other operational needs. The offering is exclusively for the U.S. market and will be conducted by Leerink Partners and Piper Sandler. The final terms of the offering will be determined following a book-building process, and the company will announce the results post-pricing.
Read more →IVATranslation for information purpose only INVENTIVA Soci t Anonyme with a Board of Directors with a share capital of EUR 1,459,512.74 Registered office: 50, rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Registr
INVENTIVA S.A. is holding its Ordinary and Extraordinary General Meeting on November 27, 2025, in Paris, France. Shareholders will be informed about the report from the Board of Directors and vote on draft resolutions. Those wishing to attend must prove their shareholder status and may participate in person, remotely, or by proxy. The article also details procedures for voting and submitting written questions prior to the meeting, ensuring that shareholders can effectively engage with company management.
Read more →IVACombined General Meeting of November 27, 2025 - Availability of the preparatory documents
Inventiva has announced the availability of preparatory documents for its Combined General Meeting scheduled for November 27, 2025. The meeting will address the compensation policy for the new CEO, Andrew Obenshain, and the terms of departure for the former CEO, Frédéric Cren. Shareholders are encouraged to participate and can access relevant documents on the company's website.
Read more →IVAAssemblée Générale Mixte du 27 novembre 2025 - Modalités de mise à disposition des documents préparatoires
Inventiva has announced the modalities for the upcoming Mixed General Assembly scheduled for November 27, 2025. Shareholders are invited to attend the assembly in Paris, where key resolutions including the approval of the new General Director's remuneration policy will be discussed. The company is also ensuring a smooth transition following the departure of former General Director Frédéric Cren.
Read more →IVACopyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved styleIPC Instructions to The Bank of New York, as Depositary (Must be received prior to 12:00 PM Eastern Time
The meeting details outline important procedural instructions for the upcoming Joint Ordinary & Extraordinary General Meeting of Shareholders for Inventiva S.A. scheduled for November 27, 2025. Key proposals include authorization for the Board of Directors to increase share capital and approval of the CEO's compensation policy. Shareholders are encouraged to vote prior to the meeting and provided with instructions on how to cast their votes. Additionally, there are specific measures regarding preferences for stock options and waivers related to share subscriptions.
Read more →IVA▲ +6%on this news· ran to +21% by day 3
Free translation for information purpose only INVENTIVA Soci t Anonyme with a Board of Directors with a share capital of EUR 1,459,512.74 Registered office: 50, rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Re
INVENTIVA has announced the dates for its Ordinary and Extraordinary General Meeting scheduled for November 27, 2025, in Paris, France. Key agenda items include the approval of the CEO's compensation policy and the settlement agreement related to corporate governance. Shareholders will also vote on several resolutions regarding share options and potential increases in share capital to incentivize employees. This meeting represents a significant event for investor engagement and operational transparency.
Read more →IVA▲ +10.3%on this newsshared move
Inventiva annonce la mise en place d’un nouveau programme « At-The-Market » (ATM)
Inventiva has announced the establishment of an At-The-Market (ATM) offering program to raise up to $100 million through the sale of American Depositary Shares (ADS). The funds will primarily support the research and development of lanifibranor, a treatment for metabolic dysfunction-related steatohepatitis (MASH). The program allows for market-based sales to eligible investors, enhancing the company's financial flexibility.
Read more →IVA▲ +10.3%on this newsshared move
Inventiva Announces the Implementation of a New ATM Program
Inventiva has filed a shelf registration statement with the SEC for a new At-The-Market (ATM) program, allowing it to issue up to $100 million in American Depositary Shares (ADS). The proceeds will primarily finance the development of lanifibranor, a treatment for metabolic dysfunction-associated steatohepatitis (MASH). The program is designed to attract eligible investors while adhering to regulatory limits on share dilution.
Read more →IVAINVENTIVA S.A. A joint-stock company ( soci t anonyme ) with a share capital of 1,391,512.74 euros Registered office: 50, rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255 Table of Contents
Inventiva S.A. has registered a detailed filing with the Dijon Trade and Companies Register, outlining various financial obligations and contracts related to its operations. This includes multiple finance contracts with the European Investment Bank and a warrant agreement. The company's filings also hint at upcoming financing arrangements and clinical trials. However, the specific operational or financial performance implications remain unclear from the filings.
Read more →IVASubscription Agreement for [ABSAs]/[PFW-BSAs] INVENTIVA S.A. 50, rue de Dijon 21121 Daix France The undersigned, [ ] [acting in the name and on behalf of the investment funds it represents or advises listed hereafter] (t
Inventiva S.A. has entered into a subscription agreement for the issuance of ABSAs and PFW-BSAs, which comprises new ordinary shares and warrants. This transaction is projected to raise a total of approximately €115.57 million, aimed at bolstering the company's capital for future initiatives. The closing of this agreement is contingent upon several conditions, including the timely receipt of necessary documentation and funds. The transaction outlines specific terms for the subscription price and exercise evaluations for the attached warrants.
Read more →IVATranslation for information purpose only INVENTIVA Soci t Anonyme with a Board of Directors with a share capital of EUR 956,623.91 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register
INVENTIVA is set to hold its ordinary and extraordinary general meeting on May 22, 2025, in Paris. Shareholders will be able to participate either physically, remotely, or by proxy, as detailed in the notice published in the Bulletin des Annonces Légales Obligatoires. The agenda remains unchanged and includes readings of the reports from the Board of Directors and Statutory Auditors. Shareholders must prove their status to participate and have options for remote voting.
Read more →IVA▲ +9%on this news
Translation for information purpose only INVENTIVA Soci t Anonyme with a Board of Directors With a share capital of EUR 956,623.91 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register
INVENTIVA S.A. is scheduled to hold its Ordinary and Extraordinary General Meeting on May 22, 2025. Key agenda items include the approval of the statutory and consolidated financial statements for the financial year ending December 31, 2024, which show a substantial net loss. The meeting will also address the allocation of this loss and the approval of various agreements related to capital raising and executive compensation. This follows a trend of financial underperformance since the Company's inception.
Read more →IVASubscription Agreement for T1 bis [Shares] [Pre-Funded Warrants] INVENTIVA S.A. 50, rue de Dijon 21121 Daix France Inventiva S.A., a soci t anonyme organized under the laws of the French Republic, with a share capital of
Inventiva S.A. has entered into a subscription agreement for the issuance of 34,600,507 new ordinary shares and 35,399,481 pre-funded warrants. This funding is part of a broader transaction that involves additional units, potentially reaching an aggregate amount of approximately 116 million euros. The subscription agreement stipulates conditions that must be met for the transaction to proceed, including the absence of material adverse changes. The subscription price is set at 1.35 euros per share and 1.34 euros per warrant.
Read more →IVATranslation for information purpose only INVENTIVA French soci t Anonyme with a Board of Directors with a share capital of EUR 870,776.95 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Re
INVENTIVA has announced the agenda for its combined General Meeting scheduled for December 11, 2024. This meeting will take place at a specific location in Dijon, France, and will be broadcasted live on the company's website. An amendment to the Deputy Chief Executive Officer's compensation policy will be discussed, along with other items from the Board of Directors' reports. Shareholders will be able to participate either in person or remotely, with specific guidelines set forth for voting and proxy submissions.
Read more →IVACopyright © 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved styleIPC Instructions to The Bank of New York Mellon, as Depositary (Must be received prior to 12:00 PM Eastern Time
The article outlines the formalities required for shareholders of Inventiva S.A. to exercise their voting rights at an upcoming Joint Ordinary & Extraordinary General Meeting. It details the proposal items, including amendments to director compensation policies and authorizations for share issuances without preemptive rights. Significant focus is placed on the cancellation of shareholders' preferential subscription rights in various contexts, which could affect shareholder equity.
Read more →IVAFree translation for information purpose only INVENTIVA Soci t Anonyme with a Board of Directors With a share capital of EUR 870,776.95 Registered office: 50, rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Regi
INVENTIVA has announced its Ordinary and Extraordinary General Meeting set for December 11, 2024. The agenda includes appointing new directors, approving compensation policies, and a proposed capital increase through new share issuances. These discussions aim to drive corporate governance and financial growth, though they also raise potential concerns over shareholder dilution and governance complexity. The meeting will be accessible through a live broadcast on the company’s website, promoting transparency.
Read more →IVASubscription Agreement for T1 [Shares] [Pre-Funded Warrants] INVENTIVA S.A. 50, rue de Dijon 21121 Daix France Inventiva S.A., a soci t anonyme organized under the laws of the French Republic, with a share capital of 524
Inventiva S.A. has announced a subscription agreement for T1 Shares and Pre-Funded Warrants, with a potential maximum subscription price of €116 million, contingent on certain conditions and approvals. The transaction will allow for new Ordinary Shares and warrants to be issued, but is still pending approval from the Board of Directors and the French Financial Markets Authority. The exact number of shares and warrants will be determined by the company's Board.
Read more →IVAINVENTIVA S.A. A joint-stock company ( soci t anonyme ) with a share capital of 524,771.88 euros Registered office: 50, rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255 INTERIM FINANCIAL RE
Inventiva S.A. has released its interim financial report for the first half of 2024, revealing ongoing developments in its clinical-stage biopharmaceutical projects. The company is focused on advancing lanifibranor, its lead product candidate for metabolic dysfunction-associated steatohepatitis (MASH/NASH). Despite facing challenges such as trial delays caused by COVID-19 and geopolitical factors, Inventiva has reported positive trial results and modifications to accelerate enrollment. The company's revised study design aims to enhance access to treatment for patients in clinical trials.
Read more →IVARoyalty Certificate Subscription Agreement INVENTIVA 50, rue de Dijon 21121 Daix France The undersigned, [ ] (the Subscriber ) hereby confirms its agreement with you as follows: 1. This Royalty Certificate Subscription A
Inventiva has entered into a Royalty Certificate Subscription Agreement, allowing subscribers to purchase royalty certificates under specific terms and conditions. The agreement stipulates the closing date and payment procedures through Soci t G n rale Securities Services. The transaction is contingent upon the satisfaction of several conditions, including the accuracy of representations and the completion of necessary documentation.
Read more →IVATranslation for information purpose only INVENTIVA French soci t Anonyme with a Board of Directors with a share capital of EUR 524,771.88 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Re
INVENTIVA has announced the details for its Ordinary and Extraordinary General Meeting scheduled for June 20, 2024. The meeting will take place at Hotel Castel Burgond in Daix, France, and will cover reports from the Board of Directors and Statutory Auditors. Shareholders have been informed about their participation methods, which include voting in person, remotely, or by proxy. Additionally, shareholders must validate their ownership by June 18, 2024, to attend the meeting.
Read more →IVA▲ +5.3%on this news
Translation for information purpose only INVENTIVA Soci t Anonyme with a Board of Directors With a share capital of EUR 524,771.88 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register
INVENTIVA is holding an Ordinary and Extraordinary General Meeting on June 20, 2024, to address several agenda items, including financial approvals for 2023. The meeting will discuss a reported net loss of EUR 105,287,770.62, and multiple items regarding executive compensation. Shareholders will also vote on various authorizations for share capital increases and other corporate governance matters, reflecting significant financial challenges faced by the company.
Read more →IVAINVENTIVA S.A. A joint-stock company ( société anonyme ) with a share capital of 517,528.07 euros Registered office: 50, rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255 INTERIM F
Inventiva S.A. released its Interim Financial Report for the six months ended June 30, 2023, highlighting significant developments in their research and clinical trials. The report indicates positive results from a Phase II clinical trial of lanifibranor for treating nonalcoholic fatty liver disease in Type 2 diabetes patients. Additionally, a collaboration with Sino Biopharm for the drug's development in Greater China has gained traction, marked by milestone payments and regulatory approvals. However, the company has faced enrollment difficulties in its Phase III clinical trial due to unforeseen challenges.
Read more →IVASubscription Agreement INVENTIVA 50, rue de Dijon 21121 Daix France The undersigned, [ ] (the " Subscriber ") hereby confirms its agreement with you as follows: 1. This Subscription Agreement (including the annexes attac
Inventiva S.A. has entered into a Subscription Agreement with a Subscriber for the issuance of new shares. The agreement details the responsibilities and conditions surrounding the subscription, including payment and regulatory approvals. The Subscriber's obligations are contingent upon several conditions being met, particularly those involving regulatory compliance and the provision of necessary documentation. The Company aims to list the new shares on the Euronext Paris market, subject to these terms and conditions.
Read more →IVATranslation for information purpose only INVENTIVA French soci t Anonyme with a Board of Directors with a share capital of EUR 421,341.69 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Re
INVENTIVA has scheduled its Ordinary and Extraordinary General Meeting for May 25, 2023, at the Hôtel Oceania Le Jura in Dijon, France. The agenda includes the approval of financial statements for the fiscal year ending December 31, 2022, along with various compensation policies for board members. Shareholders are required to justify their status by May 23, 2023, to participate, either in person or via remote voting. Additional procedural details for involvement and voting options are provided.
Read more →IVAInventiva SA VIF Proof 3 Ordinary and Extraordinary General Meeting of Inventiva S.A. Date
Inventiva S.A. is preparing for its Ordinary and Extraordinary General Meeting of Shareholders scheduled for May 25, 2023. The meeting will address various resolutions including the approval of financial statements and the compensation policies for key executives. Shareholders will be voting on important matters including share buybacks and capital reductions. Votes on these resolutions must be submitted to The Bank of New York Mellon by May 19, 2023.
Read more →IVA▼ -5.1%on this news
Translation for information purpose only INVENTIVA Soci t Anonyme with a Board of Directors With a share capital of EUR 421,341.69 Registered Office : 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register
INVENTIVA has announced an Ordinary and Extraordinary General Meeting scheduled for May 25, 2023, to discuss key financial resolutions. The agenda includes the approval of financial statements that reveal a considerable net loss for the fiscal year 2022, leading to the allocation of losses to the 'Report Nouveau' account. The meeting will also address the compensations for board members and related-party agreements, highlighting ongoing financial challenges faced by the company.
Read more →IVATranslation for information purpose only INVENTIVA Soci t Anonyme with a Board of Directors With a share capital of EUR 421,341.69 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register
INVENTIVA has announced the details of its Ordinary and Extraordinary General Meeting scheduled for January 25, 2023, at Hôtel Oceania Le Jura, Dijon, France. The agenda remains unchanged from the notice previously published. Shareholders are informed about their options for participating, including physical attendance and remote voting. Furthermore, the company outlined the requirements for proxy appointments and the submission of written questions ahead of the meeting.
Read more →IVA▲ +11.4%on this newsshared move
Please separate carefully at the perforation and return just this portion in the envelope provided. Ordinary and Extraordinary General Meeting of Inventiva S.A. Ordinar y an d Extraordinar y Genera l Meetin g o f Inventi
Inventiva S.A. convened an Ordinary and Extraordinary General Meeting to discuss several key resolutions, including the delegation of authority to the Board of Directors for increasing share capital and granting shares to employees. Various proposals were put forward, such as issuing ordinary shares while waiving shareholders' preferential rights. The agenda included items pertaining to corporate governance changes and planned increases in share capital through different mechanisms. The meeting materials will be available on the company's website, and voting instructions must be submitted by a specified date.
Read more →IVA▼ -21.6%on this news
Inventiva provides an update on the development of cedirogant by AbbVie Daix (France), Long Island City (New York, United States)
an update on the development of cedirogant by AbbVie (France), Long Island City (New York, United States), October 31, 2022 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for t
Read more →IVAInventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China Sino Biopharm a leading Chinese pharmaceutical group, through CTTQ will oversee the de
Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China (France), Long Island City (New York, United States), Beijing/Hong Kong (China), September 21 2022 - Inventiva (Euronext Paris and Nasdaq: IVA)
Read more →IVACERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT (INDICATED BY [***]) HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT INVENTIVA S.A. TREATS AS
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT (INDICATED BY [***]) HAS BEEN OMITTED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT INVENTIVA S.A. TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AND COLLABORA
Read more →IVA▲ +5.2%on this news
Update on Inventiva's cash position and on the finance documentation with the European Investment Bank Inventiva successfully raised approximately 14.6 million through a combination of its ATM Program for 9
Update on Inventiva's cash position and on the finance documentation with the European Investment Bank Daix (France), Long Island City (New York, United States), July 4, 2022 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical comp
Read more →IVAResults of the votes of the Combined Shareholders' Meeting of
Results of the votes of the Combined Shareholders' Meeting (France), Long Island City (New York, United States), May 20, 2022 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies f
Read more →IVADESCRIPTION OF THE SHARE REPURCHASE PROGRAM AUTHORISED BY THE ORDINARY GENERAL MEETING OF 19 MAY 2022 Daix
THE SHARE REPURCHASE PROGRAM AUTHORISED BY THE ORDINARY GENERAL MEETING OF 19 MAY 2022 241-2 of the AMF General Regulations (R glement G n ral de l'Autorit des march s financiers), the purpose of this description is to present the objectives and terms of the share repurchase pr
Read more →IVAInventiva secures a 50 million credit facility from the European Investment Bank This credit facility is intended to support the progress and expansion of Inventiva's pipeline The credit facility consists o
Inventiva secures a 50 million credit facility from the European Investment Bank Daix (France), Long Island City (New York, United States), May 16, 2022 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the de
Read more →IVATranslation for information purpose only INVENTIVA Soci t Anonyme with a Board of Directors With a share capital of EUR 408,735.51 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register
Translation for information purpose only Soci t Anonyme with a Board With a share capital of EUR 408,735.51 Registered Office: 50, Rue de Dijon, 21121 Daix 537 530 255 Trade and Companies Register of Dijon The shareholders of INVENTIVA are informed that the Ordinary and Ext
Read more →IVACombined General Meeting of
General Meeting of May 19, 2022 of the preparatory documents (France), Long Island City (New York, United States), April 28, 2022 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapie
Read more →IVAInventiva S.A. INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page Unaudited Interim Condensed Consolidated Financial Statements as of
TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL Page Unaudited Interim Condensed Consolidated Financial Statements as of March 31, 2021 and for the Three Months Ended March 31, 2021 and 2020 Unaudited Interim Condensed Consolidated Statement of Financial Position as of M
Read more →Competitive Position
How IVA ranks across every disease it competes inCompetitive Position is a premium feature
See how IVA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial